About Us

FabRx was created by leading academics at University College London (UCL), with  a passion for developing better medicines using 3D printing. We believe in a world where medical treatment can be personalised to the individual needs of each patient (in terms of dosage, shape, size and dose combinations) for production on site in pharmacies or clinical trials units. In this way, medicine taking is easier, more effective and associated with better patient outcomes.

Established in 2014, FabRx is a small start-up company with a big vision. Using our patented technologies, we provide a novel and flexible platform for the production of personalised medicines, revolutionising medical treatment for patients around the world. The future of medicine is 3D.

Meet The Team

Jack Davenport

Business Development Manager

Jack Davenport is the Business Development Manager at FabRx. Jack joined the company in September 2020 after completing his MSc in Pharmaceutical Formulation and Entrepreneurship at UCL, where he worked with Dr Goyanes and Prof Basit for his Master’s thesis on anti-counterfeit technologies using 3D printing. Prior to this he completed his undergraduate degree in Biochemistry at Imperial College London where he focused on synthetic biology, oncology and metabolic engineering. Jack hopes to use his combined knowledge of the life sciences and business industries to support the growth of FabRx.

Alvaro Goyanes

Founding Partner and Director

Dr Alvaro Goyanes is the Development Director and lead project researcher at FabRx. Alvaro holds a PhD in pharmaceutical technology and has more than 10 years’ experience in Pharmaceutics spanning Industry and Academia. He was one of the first researchers assessing opportunities of 3D printing using Fused Deposition Modeling (FDM) to manufacture oral dosage forms and medical devices. Before moving to FabRx, he was a Postdoctoral Researcher at UCL School of Pharmacy researching about 3D printed medicines for oral drug delivery. He led also formulation development projects for pharmaceutical companies and managed multiple research projects of MSc and Ph.D. students evaluating multiple technologies for drug delivery. Prior to this, he worked for 3 years as a Registered Pharmacy, thus has first-hand knowledge of the needs in terms of medicines in the community pharmacy.

Carlos Rial

Senior Software Engineer

Carlos Rial holds a Computer Engineering degree from the University of Santiago de Compostela. He carried out an internship at Altia Consultores where he took part as a business intelligence consultant in a project to improve the company's decision making. Before joining FabRx, he completed his degree thesis on the development of a software system for printing scaled data matrix codes which meet the patient dose requirements and contain information that can later be consulted using a mobile device. He enjoys developing various software applications in different fields and thrives in challenging environments.

Abdul Basit

Founding Partner and Director

Professor Abdul Basit is the Formulation Director at FabRx and he holds the position of Professor of Pharmaceutics at the UCL School of Pharmacy, University College London. Abdul's research sits at the interface between pharmaceutical science and gastroenterology, forging links between basic science and clinical outcomes. He is an international authority on oral drug delivery and absorption, and has published over 300 papers, book chapters, abstracts, and patents. He leads a large and multi-disciplinary research group, and the goal of his work is to further the understanding of gastrointestinal physiology by fundamental research. So far, this knowledge has been translated into the design of new technologies and improved disease treatments, many of which are currently in late stage clinical trials, his commercial view led to the creation of a drug delivery company, Intract Pharma. Abdul was the recipient of several awards including the Young Investigator Award in Pharmaceutics and Pharmaceutical Technology from the American Association of Pharmaceutical Scientists (AAPS), and is the only non-North American scientist to receive this award. He is a frequent speaker at international conferences, serves as a consultant to numerous pharmaceutical companies and is on the advisory boards of healthcare organizations, charitable bodies and scientific journals.

Simon Gaisford

Founding Partner and Director

Professor Simon Gaisford is the Printing Technology Director at FabRx. He is also Professor of Pharmaceutics and Head of Department of Pharmaceutics at UCL School of Pharmacy. Simon is a world-leading expert in 3D and ink-jet printing and he runs a successful group at UCL looking at 3D printing for fabricating tablets and drug-loaded medical devices. He is also an expert in the physicochemical characterisation of printed pharmaceuticals and his group houses one of the largest centres for pharmaceutical thermal analysis in the world. He has published extensively in the emerging field of printing of pharmaceutical products (2D and 3D printing), research that led to the founding of FabRx.

Bill Lindsay

Founding Partner and Director

Dr Bill Lindsay trained as a molecular biologist at the University of Oxford and the Salk Institute in San Diego, before moving to commercial roles within Thermo Electron Corporation (now Thermo Scientific) firstly as Principle Scientist within their Molecular Biology division, latterly as Director of New Products and IP Manager for the division. In 2004 Bill moved into university technology transfer, firstly as Commercial Development Manager at the School of Pharmacy, London, and more recently following merger of the School of Pharmacy with University College London as Senior Business Manager for UCL Business. Bill has been involved in many types of business transaction, from licence negotiation and spin-out company formation within the university to corporate merger and acquisition.

Copyright © 2018 FabRx Ltd